Navigating Regulatory Risks in APAC Life Sciences: Insights from the SCCA Legal Congress 2026
The legal and regulatory landscape for life sciences companies in the Asia-Pacific (APAC) region is currently undergoing a period of rapid acceleration. Driven by geopolitical shifts and intensifying enforcement, in-house legal and compliance teams are facing a complex environment that requires proactive strategies to maintain operational stability.
The SCCA Asia-Pacific Legal Congress 2026
The SCCA Asia-Pacific Legal Congress 2026, hosted by the Singapore Corporate Counsel Association, serves as a premier event for corporate in-house legal counsel. Taking place from April 8–9, 2026, at the One Farrer Hotel in Singapore, the congress brings together over 1,600 delegates to discuss actionable insights for navigating evolving regulatory frameworks.
Critical Regulatory Pressures in 2026
Life sciences companies are currently contending with two primary pressures: international legislative restrictions and localized enforcement trends.
The Impact of the U.S. BioSecure Act
The newly enacted U.S. BioSecure Act has introduced complex restrictions for companies with exposure to China. This legislation creates significant challenges for cross-border operations, forcing legal teams to re-evaluate their supply chains and partnerships to ensure compliance with U.S. Law while maintaining their presence in the APAC market.
Heightened Scrutiny in China
Simultaneously, Chinese regulators are sharpening their focus on specific compliance areas. Key areas of scrutiny include:
- HCP Fee-for-Service Arrangements: Increased oversight on how healthcare professionals are compensated.
- Third-Party Sponsorships: Stricter rules regarding the funding and management of external partnerships.
- Charitable Patient Support Programs: A shift in how these programs are monitored to ensure they meet regulatory expectations.
Key Takeaways for Legal and Compliance Teams
- Anticipate Geopolitical Risk: Legislative actions like the BioSecure Act demonstrate that geopolitical tensions directly impact operational legality.
- Localize Compliance: Compliance expectations on the ground in China are shifting; “standard” global policies may not be sufficient to meet local regulatory rigor.
- Prioritize Actionable Insights: Moving from theoretical risk assessment to practical application is essential for mitigating enforcement actions.
Beyond Life Sciences: MoFo’s Regional Footprint
While regulatory risk in life sciences is a primary focus, the broader legal environment in APAC continues to evolve. Morrison Foerster has remained active across various sectors, including advising on the restructuring of Japan’s pro golf tour for the Nippon Sangyo Suishin Kiko Group (NSSK) and providing guidance on AI infrastructure bottlenecks and private equity trends for 2026.
Frequently Asked Questions
What is the BioSecure Act?
The BioSecure Act is a U.S. Law that introduces restrictions on companies with specific exposures to China, impacting how life sciences firms manage their cross-border operations.
Where is the SCCA Asia-Pacific Legal Congress 2026 being held?
The event is held at the Read Room of the One Farrer Hotel, 1 Farrer Park Station Road, Singapore.
Who should attend the SCCA Congress?
The event is designed for corporate in-house legal counsel and compliance teams operating within the APAC region.
Related reading